Compare AbCellera Biologics Inc (ABCL) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? AbCellera Biologics Inc trades at $7.27 (market cap $2.35B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.65. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | VTIP | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $50.75 |
52-Week Low | $2.78 | $49.39 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
VTIP (Vanguard Short-Term Inflation-Protected Securities ETF) trades at $49.64 with minimal daily movement (+0.12%). The technical picture shows conflicting signals with moving averages indicating bearish pressure while oscillators suggest potential oversold conditions. Recent news highlights VTIP's role as an inflation hedge, with multiple institutional investors increasing positions. The ETF focuses on short-term Treasury Inflation-Protected Securities, designed to protect against rising consumer prices.
VTIP offers investors exposure to inflation-protected government bonds with lower duration risk than longer-term TIPS funds. Current market conditions favor inflation-hedging assets, though the fund faces risks from potential Fed policy shifts and interest rate volatility. The ETF's structure provides built-in CPI adjustment, making it relevant in the current inflationary environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
